Vascular protection to increase the safety of tissue plasminogen activator for stroke

Current Pharmaceutical Design

Volumn 18, Issue 25, 2012, Pages 3677-3684

  Ishrat, Tauheed ^a   Soliman, Sahar ^a   Guan, Weihua ^a   Saler, Mihaela ^a   Fagan, Susan C ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Blood brain barrier; Hemorrhagic transformation (HT); Ischemic stroke; Matrix metalloproteinases (MMPs); Thrombolysis; Tissue plasminogen activator (tPA); Vascular protection

Indexed keywords

3 [3 (4 AMIDINOBENZAMIDO)PROPIONAMIDO] 2 (4 ETHYLBENZENESULFONAMIDO)PROPIONIC ACID; ACTIVATED PROTEIN C; ALBUMIN; CASPASE 8; DISUFENTON SODIUM; ESTRADIOL; GELATINASE A; GELATINASE B; LIPOCORTIN 2; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRILYSIN; MELATONIN; NEUROSERPIN; SCAVENGER; STROMELYSIN; TACROLIMUS; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

BLEEDING; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BLOOD PRESSURE; BLOOD VESSEL INJURY; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAST CELL DEGRANULATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

BLOOD PRESSURE; BLOOD-BRAIN BARRIER; HEMORRHAGE; HUMANS; HYPERGLYCEMIA; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84867563380     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802002779     Document Type: Review

References (88)

1. Feigin VL. Stroke epidemiology in the developing world. Lancet 2005; 365: 2160-1.
2. The NINDS t-pa stroke study group: Intracerebral hemorrhage after intravenous t-pa therapy for ischemic stroke. Stroke 1997; 28: 2109-18.
3. Goldstein LB. Acute ischemic stroke treatment in 2007. Circulation 2007; 116: 1504-14.
4. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007; 24: 1-10.
5. Marder VJ, Jahan R, Gruber T, Goyal A, Arora V. Thrombolysis with plasmin: implications for stroke treatment. Stroke 2010; 41: S45-9.
6. Tissue Plasminogen Activator For Acute Ischemic Stroke. The National Institute of Neurological Disorder and Stroke rt-PA Stroke Study Group. NEJM 1995; 333(24): 1581-7.
7. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. NEJM 2008; 359(13): 1317-1329.
8. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283(9):1151-8.
9. Kastrup A, Groschel K, Ringer TM, Redcker C, et al. Early Disruption of the Blood-Brain Barrier After Thrombolytic Therapy Predicts Hemorrhage in Patients With Acute Stroke. Stroke 2008; 39: 2385-7.
10. Levy DE, Brott TG, C HE, Marler JR, Sheppard GL, Barsan W, Broderick JP. Factors related to intracranial hematoma formation in patients receiving tPA for acute ischemic stroke. Stroke 1994; 25: 291-7.
11. Powers WJ. Acute Hypertension After Stroke; the Scientific Basis for Treatment Decisions. Neurology 1993; 43: 461-7.
12. Brott T, Lu M, Kothari R, et al. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke 1998; 29: 1504-9.
13. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. Neurology 2002; 59: 699-74.
14. Butcher K, Christensen S, Parsons M, et al. EPITHET Investigators. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke 2010; 41(1): 72-7.
15. Tsivgoulis, G, Fey, JL, Flaster, M, et al. Pre-Tissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage. Stroke 2009; 40: 3631-3634.
16. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology 2001; 57(9): 1603-10.
17. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD. Canadian Alteplase for Stroke Effectiveness Study Investigators. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care 2009; 32(4): 617-22.
18. Gravanis I, Tsirka SE. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets 2008; 12(2): 159-70.
19. Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol 1994; 144(5): 855-61.
20. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38(3): 376-85.
21. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 2008; 7(3): 243-53.
22. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17(2): 543-52.
23. Siao CJ, Fernandez SR, Tsirka SE. Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci 2003; 23(8): 3234-42.
24. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7(1): 59-64.
25. Liu D, Cheng T, Guo H, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004; 10(12): 1379-83.
26. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxininduced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377(6547): 340-4.
27. Abu Fanne R, Nassar T, Yarovoi S, et al. Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology 2010; 58(7): 972-80.
28. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 4(2): 228-31.
29. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99(18): 2440-4.
30. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997; 238(1-2): 53-6.
31. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 2007; 5(8): 1732-9.
32. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997; 23(5): 406-15.
33. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005; 50(4): 329-39.
34. Rivera S, Ogier C, Jourquin J, et al. Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur J Neurosci 2002; 15(1): 19-32.
35. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21(19): 7724-32.
36. Lee SR, Tsuji K, Lo EH. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 2004; 24(3): 671-8.
37. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34(1): 40-6.
38. Montaner J, Molina CA, Monasterio J, et al Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107(4): 598-603.
39. Zhao BQ, Wang S, Kim HY, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006; 12(4): 441-5.
40. Lo EH, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke 2004; 35(2): 354-6.
41. Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002; 33(11): 2711-7.
42. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33(3): 831-6.
43. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9(10): 1313-7.
44. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112(10): 1533-40.
45. Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 2001; 29(3): 571-81.
46. Harris-White ME, Frautschy SA. Low density lipoprotein receptorrelated proteins (LRPs), Alzheimer's and cognition. Curr Drug Targets CNS Neurol Disord 2005; 4(5): 469-80.
47. Strbian D, Karjalainen-Lindsberg ML, Kovanen PT, Tatlisumak T, Lindsberg PJ. Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 2007; 116(4): 411-8.
48. Lapchak PA, Song D, Wei J, Zivin JA. Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence. Exp Neurol 2004; 188(2): 286-91.
49. Hoyte L, Kaur J, Buchan AM. Lost in translation: taking neuroprotection from animal models to clinical trials. Exp Neurol 2004; 188(2): 200-4.
50. Schatlo B, Henning EC, Pluta RM, et al. Nitrite does not provide additional protection to thrombolysis in a rat model of stroke with delayed reperfusion. J Cereb Blood Flow Metab 2008; 28(3): 482-9.
51. Haelewyn B, David HN, Colloc'H N, Colomb DG Jr, Risso JJ, Abraini JH. Interactions between nitrous oxide and tissue plasminogen activator in a rat model of thromboembolic stroke. Anesthesiology 2011; 115(5): 1044-53.
52. Pfeilschifter W, Spitzer D, Pfeilschifter J, Steinmetz H, Foerch C. Warfarin Anticoagulation Exacerbates the Risk of Hemorrhagic Transformation after rt-PA Treatment in Experimental Stroke: Therapeutic Potential of PCC. PLoS One 2011; 6(10): e26087.
53. Fagan SC, Hess DC, Machado LS, Hohnadel EJ, Pollock DM, Ergul A. Tactics for vascular protection after acute ischemic stroke. Pharmacotherapy 2005; 25(3): 387-395.
54. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40: e647-56.
55. Zechariah A, ElAli A, Hermann DM. Combination of tissueplasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke 2010; 41(5): 1008-12.
56. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001; 21: 2-14.
57. Maier CM, Hsieh L, Crandall T, Narasimhan P, Chan PH Evaluating therapeutic targets for reperfusion related brain hemorrhage. Ann Neurol 2006; 59: 929-38.
58. Kano T, Harada T, Katayama Y. Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. Neurol Res 2005; 27(5): 499-502.
59. Yamashita T, Kamiya T, Deguchi K, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 2009; 29: 715-25.
60. Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000; 20(3): 452-7.
61. Lapchak PA, Chapman DF, Zivin JA. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6- tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2001; 32(1): 147-53.
62. Chen TY, Lee MY, Chen HY, et al. Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J Pineal Res 2006; 40(3): 242-50.
63. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA. Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke 2002; 33(6): 1665-70.
64. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tertbutylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2002; 33(5): 1411-5.
65. Lapchak PA, Song D, Wei J, Zivin JA. Coadministration of NXY059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 2004; 188(2): 279-85.
66. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006; 354: 588-600.
67. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357: 562-71.
68. Machado LS, Sazonova IY, Kozak A, et al. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke 2009; 40(9): 3028-33.
69. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 2007; 22: E4.
70. Tsuji K, Aoki T, Tejima E, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005; 36: 1954-9.
71. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000; 31(12): 3034-40.
72. Copin JC, Merlani P, Sugawara T, Chan PH, Gasche Y. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol 2008; 213(1): 196-201.
73. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 2008; 39(12): 3372-7.
74. Fagan SC, Cronic LE, Hess DC. Minocycline Development for Acute Ischemic Stroke. Transl Stroke Res 2011; 2(2): 202-8.
75. López-Atalaya JP, Roussel BD, Ali C, et al. Recombinant Desmodus rotundus salivary plasminogen activator crosses the bloodbrain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 2007; 38(3): 1036-43.
76. Suzuki Y, Nagai N, Yamakawa K, Kawakami J, Lijnen HR, Umemura K. Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. Blood 2009; 114(15): 3352-8.
77. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 2006; 26: 605-12.
78. Strbian D, Tatlisumak T, Abo Ramadan U, Lindsberg PJ. Mast cell blocking reduces brain edema and hematoma volume and improves outcome after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 2007; 27: 795-802.
79. Kasahara Y, Nakagomi T, Matsuyama T, Stern D, Taguchi A. Cilostazol Reduces the Risk of Hemorrhagic Infarction After Administration of Tissue-Type Plasminogen Activator in a Murine Stroke Model. Stroke 2011; doi: 10.1161/STROKEAHA.111.635417.
80. Lapchak PA, Araujo DM, Song D, Zivin JA. The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke. Stroke 2002; 33(1): 147-52.
81. Tang J, Li YJ, Mu J, Li Q, Yang DY, Xie P. Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats. Neurol Res 2009; 31(2): 189-94.
82. Zhu H, Fan X, Yu Z, et al. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab 2010; 30(6): 1137-46.
83. Griffin JH, Fernández JA, Liu D, Cheng T, Guo H, Zlokovic BV. Activated protein C and ischemic stroke. Crit Care Med 2004; 32(5 Suppl): S247-53.
84. Cheng T, Petraglia AL, Li Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12(11): 1278-85.
85. Li M, Zhang Z, Sun W, Koehler RC, Huang J. 17β-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia. Neurobiol Dis 2011; 44(3): 277-83.
86. Liu R, Liu Q, He S, Simpkins JW, Yang SH. Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. J Pharmacol Exp Ther 2010; 332(3): 1006-12.
87. Zhang Z, Zhang L, Yepes M, et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002; 106(6): 740-5.
88. Maeda M, Furuichi Y, Noto T, Matsuoka N, Mutoh S, Yoneda Y. Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model. Brain Res 2009; 1254: 99-108.